[Retrobulbar corticotherapy].
Corticotherapy has been proposed several times for the treatment of venous thrombosis of the retina (e.g., Hayreh 1975). Since 1975 the present authors have used it regularly, combined with heparinotherapy, for all types of retinal vascular occlusion, in the form of retrobulbar injections of corticoids. The aim is to reduce edema of the vascular wall at the occlusion and re-establish or improve the flow, and thereby protect the sensory cells during the critical repair period. In edematous or mixed types of venous thrombosis, the effectiveness of the treatment is demonstrated by a rapid improvement in acuity. As recommended by Hayreh, corticotherapy is certainly indicated for edematous and mixed thromboses with loss of central field acuity. In other types of vascular occlusions (ischemic venous thrombosis, arterial occlusion, and vascular papillitis) the benefit can only be guessed at. Corticotherapy is not a replacement for anticoagulation, laser coagulation, or general treatment.
D000368:Aged; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007267:Injections / Q000379:methods; D008297:Male; D008875:Middle Aged; D012161:Retinal Artery; D012164:Retinal Diseases / Q000188:drug therapy; D012169:Retinal Vein; D013927:Thrombosis / Q000188:drug therapy*
C018230:betamethasone acetate phosphate; C028994:betamethasone sodium phosphate; D006493:Heparin; D001623:Betamethasone
La corticothérapie par voie rétro-bulbaire.